Nordic Bioproducts Group opens its first major production facility for advanced cellulosic materials

Finnish startup Nordic Bioproducts Group has opened its state-of-the-art production facility in Lappeenranta, Finland. This facility, powered by the company’s proprietary AaltoCellTM Technology, is dedicated to the commercial-scale production of advanced cellulosic materials, including its flagship Microcrystalline Cellulose (MCC). The factory is expected to create 40 million euros in revenue in the first full operating year.

HELSINKI, Finland (April 24th, 2024) – Nordic Bioproducts Group (NBG), a leader in biomaterial innovation and developer of proprietary AaltoCellTM Technology, announces the opening of its commercial-scale production facility for microcrystalline cellulose (MCC) and other cellulose derivatives in Lappeenranta, Finland. This first-of-its-kind facility represents a significant leap in manufacturing, enabling continuous and sustainable production at scale.

Featuring the world’s first continuous production line of up to 10,000 tons of MCC annually, the facility was designed to ensure quality and purity in MCC production. It also prioritizes environmental sustainability by producing zero solid waste and using only a fraction of the chemicals, water, and electricity compared to traditional MCC production processes. Furthermore, based on the findings of an independent third-party study, the process achieves a significant 72% reduction in greenhouse gas emissions compared to traditional methods.

Microcrystalline cellulose and other cellulose derivatives are valuable ingredients utilized across diverse industries, enriching product properties and performance. Moreover, the use of cellulosic materials fosters environmental sustainability by replacing non-sustainable and potentially harmful substances in a range of applications such as bioplastics, concrete, paints, textiles, glues, and insulation.

As the purest and most versatile form of cellulose, microcrystalline cellulose has been used in a range of industries for decades – from pharmaceuticals and food supplements to food ingredients, cosmetics, and skincare. The global demand for MCC is high, and the market is projected to grow exponentially by 2030.

“The world was changed when crude oil was discovered, and now it is time to revolutionize the world with cellulose-based materials! Our goal is to bring ground-breaking solutions to the market that don’t cause negative environmental impact. This factory is a big investment in the green transition, and we would like to invite all companies to join us in thinking about how can we ensure that the planet survives for the next generation. We can’t do it alone, but our mass production facility for cellulosic products, like MCC, is a good start,” says Olli K?hk?nen, CEO and co-founder of Nordic Bioproducts Group Ltd .

Lappeenranta was chosen as the location due to its closeness to six existing pulp manufacturing plants, local supply, and short access to seaports, ensuring supply chain security. Additionally, all ingredients come from FSC-certified, traceable, sustainably managed forests. The factory has been built to meet modern standards, being people-centric and enforcing employee satisfaction.

The first production phase started in March 2024, and now, the factory is gearing up to its full production capacity of up to 10,000 tons of MCC produced annually. The factory is expected to create 40 million euros in revenue in the first full operating year, aiming to triple the revenue in the following three years. The new factory employs 20 people and intends to double that number in the near future.

Nordic Bioproducts Group already has ongoing partnerships globally, including collaborations with Asian corporations Marubeni and Thailand’s PTT MCC. With the full production capacity now operational, the company is poised to welcome clients from various industries and countries.

“Our innovative product meets the future needs of the market and the most strict ExciPact certificate requirements. Already today we have ongoing cooperation with leading pharmaceutical, bioplastics, and nutraceutical companies and distributors. We welcome all to test and try our MCC and other derived cellulose products to see the full potential,” concludes K?hk?nen.

A spinoff from Aalto University, Nordic Bioproducts Group was founded in 2019 by Professor Olli Dahl and then Senior Commercial Officer Olli K?hk?nen in cooperation with the Aalto University School of Chemical Engineering.

###

More information on Nordic Bioproducts on pharmaexcipients.com -

For additional information:

Media kit with pictures

Olli K?hk?nen, CEO and co-founder Nordic Bioproducts Group [email protected]

About Nordic Bioproducts Group

Nordic Bioproducts Group Oy (“NBG”), founded in 2019 as a spin-off from Aalto University, stands at the forefront of cellulose innovation, bioproduct development, and commercialization in the Nordics.

At the heart of its mission is a commitment to optimizing the use of renewable natural resources while reducing the world’s dependence on fossil-based resources, fostering circular solutions, and catalyzing impactful change on a global scale.

As a pioneering force, the company is dedicated to introducing breakthrough technologies and biomaterials that redefine the landscape of sustainable solutions.

The company’s head office is in Espoo, Finland. More information: nordicbioproducts.fi